Initial Evidence of the Beneficial Effects of Glutamate-Modulating Agents in the Treatment of Self-Injurious Behavior Associated With Borderline Personality Disorder
Christopher Pittenger, MD, PhD; John H. Krystal, MD; and Vladimir Coric, MD
J Clin Psychiatry 2005;66(11):1492-1493 [letter]
© Copyright 2015 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
-
-
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
-
Subscribe
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
-
-
Activate
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
-
Sign in
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
-
Click here to login.
-
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
Sir: Self-injurious behavior (SIB) in patients with borderline
personality disorder (BPD), especially cutting, represents a
serious and often intractable clinical problem.
1 There are few
validated pharmacologic strategies for managing SIB.
1–3 We
describe our initial experience using glutamate-modulating
agents in 2 patients with BPD and prominent SIBs.